We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-12.50 | -0.70% | 1,771.00 | 1,771.00 | 1,771.50 | 1,779.00 | 1,764.50 | 1,773.50 | 5,777,098 | 16:29:57 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.81 | 72.97B |
By Tess Stynes
Five Prime Therapeutics Inc. (FPRX) said GlaxoSmithKline PLC (GSK, GSK.LN) exercised its option for an exclusive global license to products related to an undisclosed muscle-disease target discovered by the clinical-stage biotechnology company.
Five Prime shares were recently trading at $12.07, up 4.9%.
Five Prime will receive a payment of $1.5 million in connection with the option exercise and is eligible for as much as $122.5 million in milestone payments.
Five Prime and Glaxo began a collaboration in 2010 to discover and develop drug targets for skeletal muscle diseases using Five Prime's platform.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions